Suppr超能文献

肺动脉高压的死亡原因和情况。

Causes and circumstances of death in pulmonary arterial hypertension.

机构信息

Department of Pulmonary, Allergy and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA.

出版信息

Am J Respir Crit Care Med. 2013 Aug 1;188(3):365-9. doi: 10.1164/rccm.201209-1640OC.

Abstract

RATIONALE

The causes and circumstances surrounding death are understudied in patients with pulmonary arterial hypertension (PAH).

OBJECTIVES

We sought to determine the specific reasons and characteristics surrounding the death of patients with PAH.

METHODS

All deaths of patients with pulmonary hypertension (PH) followed in the Cleveland Clinic Pulmonary Vascular Program were prospectively reviewed by the PH team. A total of 84 patients with PAH (age 58 ± 14 yr; 73% females) who died between June 2008 and May 2012 were included.

MEASUREMENTS AND MAIN RESULTS

PH was determined to be the direct cause of death (right heart failure or sudden death) in 37 (44%) patients; PH contributed to but did not directly cause death in 37 (44%) patients; and the death was not related to PH in the remaining cases (n = 7; 8.3%). In three (3.6%) patients the final cause of death could not be adequately assessed. Most patients died in a healthcare environment and most received PH-specific therapies. In our cohort, 50% of all patients with PAH and 75.7% of those who died of right heart failure received parenteral prostanoid therapy. Less than half of patients had advanced healthcare directives.

CONCLUSIONS

Most patients with PAH in our cohort died of their disease; however, right ventricular failure or sudden death was the sole cause of death in less than half of patients.

摘要

背景

肺动脉高压(PAH)患者的死亡原因和情况研究不足。

目的

我们旨在确定 PAH 患者死亡的具体原因和特征。

方法

克利夫兰诊所肺血管计划中所有接受肺动脉高压(PH)治疗的患者死亡均由 PH 团队前瞻性审查。共纳入 84 例 2008 年 6 月至 2012 年 5 月期间死于 PAH(年龄 58±14 岁;73%为女性)的患者。

测量和主要结果

PH 被确定为 37 例(44%)患者直接死亡原因(右心衰竭或心源性猝死);PH 导致但未直接导致 37 例(44%)患者死亡;其余病例(n=7;8.3%)与 PH 无关。在 3 例(3.6%)患者中,最终死因无法充分评估。大多数患者在医疗环境中死亡,大多数患者接受了 PH 特异性治疗。在我们的队列中,50%的 PAH 患者和 75.7%死于右心衰竭的患者接受了肠外前列环素治疗。不到一半的患者有先进的医疗保健指令。

结论

我们队列中的大多数 PAH 患者死于疾病,但不到一半的患者右心室衰竭或心源性猝死是唯一的死亡原因。

相似文献

1
Causes and circumstances of death in pulmonary arterial hypertension.
Am J Respir Crit Care Med. 2013 Aug 1;188(3):365-9. doi: 10.1164/rccm.201209-1640OC.
2
Parenteral Prostanoid Use at a Tertiary Referral Center: A Retrospective Cohort Study.
Chest. 2016 Mar;149(3):660-6. doi: 10.1378/chest.15-1051. Epub 2016 Jan 6.
3
Causes and Circumstances of Death in Portopulmonary Hypertension.
Transplant Direct. 2021 Jun 8;7(7):e710. doi: 10.1097/TXD.0000000000001162. eCollection 2021 Jul.
4
Death in pulmonary arterial hypertension.
Am J Respir Crit Care Med. 2013 Aug 1;188(3):269-70. doi: 10.1164/rccm.201305-0898ED.
5
8
Frequency, Predictors, and Prognostic Impact of Pulmonary Artery Aneurysms in Patients With Pulmonary Arterial Hypertension.
Am J Cardiol. 2019 Feb 1;123(3):474-481. doi: 10.1016/j.amjcard.2018.10.028. Epub 2018 Nov 6.
9
Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension.
Chest. 2011 Jun;139(6):1299-1309. doi: 10.1378/chest.10-2015. Epub 2010 Dec 9.
10
Use of Parenteral Prostanoids: Important Insights for CHEST Physicians.
Chest. 2016 Mar;149(3):615-6. doi: 10.1016/j.chest.2015.11.024.

引用本文的文献

1
Pericardial Effusion and Prostacyclin Analog Toxicity After Initiation of Sotatercept.
Pulm Circ. 2025 Jul 27;15(3):e70141. doi: 10.1002/pul2.70141. eCollection 2025 Jul.
3
Treatment of pulmonary hypertension after seven world symposia.
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251342898. doi: 10.1177/17534666251342898. Epub 2025 May 23.
7
Right ventricular stroke work index from echocardiography in patients with pulmonary arterial hypertension-the role in short-term follow-up assessment.
Eur Heart J Imaging Methods Pract. 2024 Dec 3;2(3):qyae128. doi: 10.1093/ehjimp/qyae128. eCollection 2024 Jul.
8
Sudden cardiac death in pulmonary arterial hypertension.
Int J Cardiol Congenit Heart Dis. 2024 Jul 6;17:100525. doi: 10.1016/j.ijcchd.2024.100525. eCollection 2024 Sep.
9
Epicardial Adipose Tissue as an Independent Risk Factor for Mortality in Pulmonary Arterial Hypertension.
Chest. 2025 May;167(5):1481-1492. doi: 10.1016/j.chest.2024.11.020. Epub 2024 Nov 28.
10
Intestinal IFNα4 promotes 15-HETE diet-induced pulmonary hypertension.
Respir Res. 2024 Nov 28;25(1):419. doi: 10.1186/s12931-024-03046-z.

本文引用的文献

1
Optimising the management of pulmonary arterial hypertension patients: emergency treatments.
Eur Respir Rev. 2010 Sep;19(117):204-11. doi: 10.1183/09059180.00004910.
3
Diagnosis and assessment of pulmonary arterial hypertension.
J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S55-S66. doi: 10.1016/j.jacc.2009.04.011.
4
Updated clinical classification of pulmonary hypertension.
J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S43-S54. doi: 10.1016/j.jacc.2009.04.012.
5
Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension.
Am J Respir Crit Care Med. 2009 Sep 1;180(5):468-74. doi: 10.1164/rccm.200810-1603OC. Epub 2009 Jun 11.
7
Pulmonary hypertension surveillance--United States, 1980-2002.
MMWR Surveill Summ. 2005 Nov 11;54(5):1-28.
8
Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension.
Am J Respir Crit Care Med. 2002 Feb 1;165(3):341-4. doi: 10.1164/ajrccm.165.3.200109-0130c.
10
Reference equations for the six-minute walk in healthy adults.
Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 1):1384-7. doi: 10.1164/ajrccm.158.5.9710086.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验